Item Type | Name |
Concept
|
Antibiotics, Antineoplastic
|
Concept
|
Acetyl-CoA Carboxylase
|
Concept
|
Antigens, Viral
|
Concept
|
Acetylcysteine
|
Concept
|
Sodium-Potassium-Exchanging ATPase
|
Concept
|
Aminopterin
|
Concept
|
Alkaloids
|
Concept
|
Carbazoles
|
Concept
|
Antimetabolites, Antineoplastic
|
Concept
|
Antibodies, Viral
|
Concept
|
Antigens, Neoplasm
|
Concept
|
Amino Acid Chloromethyl Ketones
|
Concept
|
Antineoplastic Agents
|
Concept
|
Carnitine O-Palmitoyltransferase
|
Concept
|
Benzamides
|
Concept
|
Collagen
|
Concept
|
Bombesin
|
Concept
|
Ceramides
|
Concept
|
Cyclodextrins
|
Concept
|
Cisplatin
|
Concept
|
Creatinine
|
Concept
|
Dexamethasone
|
Concept
|
Flavonoids
|
Concept
|
Actins
|
Concept
|
Benzimidazoles
|
Concept
|
Contractile Proteins
|
Concept
|
Drug Evaluation
|
Concept
|
Contrast Media
|
Concept
|
Endoribonucleases
|
Concept
|
Diamines
|
Concept
|
Drug Evaluation, Preclinical
|
Concept
|
Endonucleases
|
Concept
|
Drug Implants
|
Concept
|
Antineoplastic Agents, Phytogenic
|
Concept
|
Aminopyridines
|
Concept
|
Acetamides
|
Concept
|
Cyclic AMP
|
Concept
|
Epitopes
|
Concept
|
Asparaginase
|
Concept
|
Antibodies, Anti-Idiotypic
|
Concept
|
Aldehyde Reductase
|
Concept
|
Antiemetics
|
Concept
|
Aspartate-Ammonia Ligase
|
Concept
|
Antibodies, Monoclonal
|
Concept
|
Heterocyclic Compounds, 3-Ring
|
Concept
|
Aldehyde Dehydrogenase
|
Concept
|
Estradiol
|
Concept
|
Exons
|
Concept
|
Benzenesulfonates
|
Concept
|
Fatty Acids
|
Concept
|
Fibroblast Growth Factors
|
Concept
|
Calcium-Binding Proteins
|
Concept
|
Camptothecin
|
Concept
|
Carbolines
|
Concept
|
Cytarabine
|
Concept
|
Azacitidine
|
Concept
|
Benzodiazepines
|
Concept
|
Microtubule-Associated Proteins
|
Concept
|
Hydrogen Peroxide
|
Concept
|
Dose-Response Relationship, Drug
|
Concept
|
Carrier Proteins
|
Concept
|
Arginine Vasopressin
|
Concept
|
Bufanolides
|
Concept
|
Binding Sites
|
Concept
|
Cyclophosphamide
|
Concept
|
Fungal Proteins
|
Concept
|
Genetic Vectors
|
Concept
|
Histone Deacetylases
|
Concept
|
Cytoskeletal Proteins
|
Concept
|
Chromones
|
Concept
|
Base Sequence
|
Concept
|
Hormones, Ectopic
|
Concept
|
Carcinogens
|
Concept
|
Hormones
|
Concept
|
Deoxyribonuclease I
|
Concept
|
Doxorubicin
|
Concept
|
Eosine Yellowish-(YS)
|
Concept
|
Epidermal Growth Factor
|
Concept
|
Microtubule Proteins
|
Concept
|
Enzyme Inhibitors
|
Concept
|
Eye Proteins
|
Concept
|
Transcription Factors
|
Concept
|
Dipeptides
|
Concept
|
DNA-Binding Proteins
|
Concept
|
Fluorescent Dyes
|
Concept
|
Ophthalmic Solutions
|
Concept
|
Estrogens
|
Concept
|
Gastrins
|
Concept
|
Follicle Stimulating Hormone
|
Concept
|
Formaldehyde
|
Concept
|
Phenanthridines
|
Concept
|
Phorbol Esters
|
Concept
|
Protein Kinase C
|
Concept
|
Drug Synergism
|
Concept
|
Polylysine
|
Concept
|
Globins
|
Concept
|
Interferon-gamma
|
Concept
|
Hepatocyte Growth Factor
|
Concept
|
Prostaglandin-Endoperoxide Synthases
|
Concept
|
Protein Kinases
|
Concept
|
Polyethylene Glycols
|
Concept
|
Promoter Regions, Genetic
|
Concept
|
Pyrimidines
|
Concept
|
Receptors, Glucocorticoid
|
Concept
|
Ribonucleases
|
Concept
|
Serine
|
Concept
|
Morpholines
|
Concept
|
Lovastatin
|
Concept
|
Quinoxalines
|
Concept
|
Cytotoxins
|
Concept
|
Membrane Proteins
|
Concept
|
Stereoisomerism
|
Concept
|
Tablets
|
Concept
|
Membrane Glycoproteins
|
Concept
|
Oncogene Proteins, Viral
|
Concept
|
Plasmids
|
Concept
|
Luminescent Proteins
|
Concept
|
Caspases
|
Concept
|
Glycoproteins
|
Concept
|
Growth Inhibitors
|
Concept
|
Platinum
|
Concept
|
Drug Design
|
Concept
|
Phenylurea Compounds
|
Concept
|
Protein-Tyrosine Kinases
|
Concept
|
Mitogens
|
Concept
|
Retinoids
|
Concept
|
RNA, Viral
|
Concept
|
HMGA1a Protein
|
Concept
|
Receptors, Vasoactive Intestinal Peptide
|
Concept
|
Neurotransmitter Agents
|
Concept
|
Isoenzymes
|
Concept
|
Transforming Growth Factor beta
|
Concept
|
Urea
|
Concept
|
Nitrogen Oxides
|
Concept
|
Organometallic Compounds
|
Concept
|
Interleukin-6
|
Concept
|
Oxidants
|
Concept
|
Transferrin
|
Concept
|
Receptors, Peptide
|
Concept
|
ATP-Binding Cassette Transporters
|
Concept
|
Apolipoprotein A-I
|
Concept
|
Proteins
|
Concept
|
Calcium
|
Concept
|
Capsules
|
Concept
|
RNA, Small Interfering
|
Concept
|
CDC2-CDC28 Kinases
|
Concept
|
Receptors, Retinoic Acid
|
Concept
|
Drug Monitoring
|
Concept
|
Acid Anhydride Hydrolases
|
Concept
|
Proto-Oncogene Proteins
|
Concept
|
Phosphoserine
|
Concept
|
Gastrin-Releasing Peptide
|
Concept
|
Cytochromes c
|
Concept
|
RNA
|
Concept
|
Adenosylmethionine Decarboxylase
|
Concept
|
Somatomedins
|
Concept
|
Peptide Fragments
|
Concept
|
Repressor Proteins
|
Concept
|
Gonadal Steroid Hormones
|
Concept
|
Oncogene Proteins
|
Concept
|
GTP-Binding Proteins
|
Concept
|
Cyclin E
|
Concept
|
Trans-Activators
|
Concept
|
Cell Adhesion Molecules
|
Concept
|
Alternative Splicing
|
Concept
|
CA-125 Antigen
|
Concept
|
Proto-Oncogene Proteins c-raf
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p16
|
Concept
|
Cyclooxygenase 2
|
Concept
|
Benzophenanthridines
|
Concept
|
Matrix Metalloproteinases, Membrane-Associated
|
Concept
|
BRCA1 Protein
|
Concept
|
Dual Specificity Phosphatase 1
|
Concept
|
Receptor, TIE-2
|
Concept
|
Recombinant Proteins
|
Concept
|
cdc42 GTP-Binding Protein
|
Concept
|
Calcineurin
|
Concept
|
Mitogen-Activated Protein Kinase 9
|
Concept
|
Tetradecanoylphorbol Acetate
|
Concept
|
Proto-Oncogene Proteins c-fos
|
Concept
|
Cyclic AMP Response Element-Binding Protein
|
Concept
|
Receptors, Fibroblast Growth Factor
|
Concept
|
TNF-Related Apoptosis-Inducing Ligand
|
Concept
|
Veratrum Alkaloids
|
Concept
|
ADP-ribosyl Cyclase
|
Concept
|
Ionomycin
|
Concept
|
Matrix Metalloproteinase 2
|
Concept
|
Neuropilin-1
|
Concept
|
Fibroblast Growth Factor 1
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
Concept
|
Homeodomain Proteins
|
Concept
|
Cyclin A
|
Concept
|
Proto-Oncogene Proteins B-raf
|
Concept
|
Early Growth Response Protein 1
|
Concept
|
Matrix Metalloproteinase 7
|
Concept
|
beta Karyopherins
|
Concept
|
Activin Receptors, Type I
|
Concept
|
Chemokine CXCL12
|
Concept
|
Monomeric GTP-Binding Proteins
|
Concept
|
Immunoconjugates
|
Concept
|
Thiourea
|
Concept
|
Phosphatidylserines
|
Concept
|
Karyopherins
|
Concept
|
Angiopoietin-2
|
Concept
|
Isotretinoin
|
Concept
|
Response Elements
|
Concept
|
3' Untranslated Regions
|
Concept
|
Gadolinium
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
Concept
|
MAP Kinase Kinase 1
|
Concept
|
MAP Kinase Kinase 2
|
Concept
|
Fluocinolone Acetonide
|
Concept
|
DNA
|
Concept
|
Doxycycline
|
Concept
|
Hematoxylin
|
Concept
|
Lipopolysaccharides
|
Concept
|
Luciferases
|
Concept
|
Piperazines
|
Concept
|
Receptors, Pituitary Hormone
|
Concept
|
Gene Library
|
Concept
|
Carboplatin
|
Concept
|
NF-kappa B
|
Concept
|
Genes, jun
|
Concept
|
HSP70 Heat-Shock Proteins
|
Concept
|
Angiogenesis Inhibitors
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
Concept
|
Chitosan
|
Concept
|
MAP Kinase Kinase 4
|
Concept
|
Receptor, Notch2
|
Concept
|
Neuropeptides
|
Concept
|
Phthalazines
|
Concept
|
Pyrroles
|
Concept
|
RNA, Messenger
|
Concept
|
Sodium Chloride
|
Concept
|
Proto-Oncogene Proteins c-jun
|
Concept
|
Histone-Lysine N-Methyltransferase
|
Concept
|
Vimentin
|
Concept
|
Paclitaxel
|
Concept
|
DEAD-box RNA Helicases
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Tumor Suppressor Protein p53
|
Concept
|
Proto-Oncogene Proteins c-myc
|
Concept
|
DNA, Neoplasm
|
Concept
|
Drug Hypersensitivity
|
Concept
|
Erythropoietin
|
Concept
|
Transcription Factor AP-1
|
Concept
|
Receptors, Interleukin-8B
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
Concept
|
Taxoids
|
Concept
|
Receptors, Scavenger
|
Concept
|
Glycogen Synthase Kinases
|
Concept
|
Adaptor Proteins, Signal Transducing
|
Concept
|
NFATC Transcription Factors
|
Concept
|
PTEN Phosphohydrolase
|
Concept
|
Transcription Factor RelB
|
Concept
|
DNA Primers
|
Concept
|
Onium Compounds
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
Concept
|
bcl-X Protein
|
Concept
|
Wnt Proteins
|
Concept
|
Glucose
|
Concept
|
Growth Substances
|
Concept
|
Small Molecule Libraries
|
Concept
|
Apoptosis Regulatory Proteins
|
Concept
|
Pituitary Adenylate Cyclase-Activating Polypeptide
|
Concept
|
Versicans
|
Concept
|
Vitamin E
|
Concept
|
Chemokine CXCL2
|
Concept
|
Protein Phosphatase 1
|
Concept
|
NM23 Nucleoside Diphosphate Kinases
|
Concept
|
Receptors, Transforming Growth Factor beta
|
Concept
|
Troponin C
|
Concept
|
Oncogene Protein p21(ras)
|
Concept
|
Antigens, CD
|
Concept
|
Immediate-Early Proteins
|
Concept
|
Receptors, Cytoplasmic and Nuclear
|
Concept
|
Inflammation Mediators
|
Concept
|
Drug Delivery Systems
|
Concept
|
Ondansetron
|
Concept
|
Drug Compounding
|
Concept
|
Drug Therapy, Combination
|
Concept
|
Cyclin-Dependent Kinases
|
Concept
|
Bleomycin
|
Concept
|
Deoxycytidine
|
Concept
|
DNA, Single-Stranded
|
Concept
|
Matrix Metalloproteinase 14
|
Concept
|
Interleukin-1alpha
|
Concept
|
Amyloid Precursor Protein Secretases
|
Concept
|
Drug Discovery
|
Concept
|
Antigens, CD34
|
Concept
|
HLA-D Antigens
|
Concept
|
Indazoles
|
Concept
|
Insulin
|
Concept
|
Quinazolines
|
Concept
|
Receptors, Progesterone
|
Concept
|
Thiazoles
|
Concept
|
Thymosin
|
Concept
|
Drug Industry
|
Concept
|
Organoplatinum Compounds
|
Concept
|
Atrial Natriuretic Factor
|
Concept
|
Vinblastine
|
Concept
|
Viral Proteins
|
Concept
|
Cyclin-Dependent Kinase 2
|
Concept
|
Smad Proteins
|
Concept
|
JNK Mitogen-Activated Protein Kinases
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
Concept
|
Tubulin Modulators
|
Concept
|
Glucocorticoids
|
Concept
|
Estrogen Antagonists
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 4
|
Concept
|
I-kappa B Kinase
|
Concept
|
Matrix Metalloproteinase 3
|
Concept
|
Sirolimus
|
Concept
|
Green Fluorescent Proteins
|
Concept
|
Proto-Oncogene Proteins c-mdm2
|
Concept
|
Hypoxia-Inducible Factor 1, alpha Subunit
|
Concept
|
Ligands
|
Concept
|
Iodine Radioisotopes
|
Concept
|
Indoles
|
Concept
|
Hydroquinones
|
Concept
|
Interleukin-2
|
Concept
|
Proto-Oncogene Proteins c-myb
|
Concept
|
ras-GRF1
|
Concept
|
Matrix Metalloproteinase 9
|
Concept
|
BRCA2 Protein
|
Concept
|
Connective Tissue Growth Factor
|
Concept
|
Heterocyclic Compounds
|
Concept
|
Maytansine
|
Concept
|
Guanosine Triphosphate
|
Concept
|
Antibodies, Monoclonal, Humanized
|
Concept
|
Luteinizing Hormone
|
Concept
|
5-Lipoxygenase-Activating Proteins
|
Concept
|
Saccharomyces cerevisiae Proteins
|
Concept
|
Quinones
|
Concept
|
Metalloendopeptidases
|
Concept
|
Gases
|
Concept
|
Oligonucleotides
|
Concept
|
LIM-Homeodomain Proteins
|
Concept
|
Heat-Shock Proteins
|
Concept
|
Ice
|
Concept
|
Nitrogen Isotopes
|
Concept
|
Naphthalenes
|
Concept
|
Oligopeptides
|
Concept
|
Oxazines
|
Concept
|
Phosphoric Monoester Hydrolases
|
Concept
|
Phosphoproteins
|
Concept
|
Prealbumin
|
Concept
|
Clusterin
|
Concept
|
Kruppel-Like Transcription Factors
|
Concept
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
|
Concept
|
Receptors, Antigen, T-Cell
|
Concept
|
Ornithine Decarboxylase
|
Concept
|
Regulatory Sequences, Nucleic Acid
|
Concept
|
Piperidines
|
Concept
|
Pyrazoles
|
Concept
|
Protease Inhibitors
|
Concept
|
Pyridines
|
Concept
|
Ki-67 Antigen
|
Concept
|
RNA-Binding Proteins
|
Concept
|
Receptors, Androgen
|
Concept
|
RNA, Neoplasm
|
Concept
|
Phosphatidylinositol 3-Kinases
|
Concept
|
Extracellular Matrix Proteins
|
Concept
|
ras Proteins
|
Concept
|
Pyrimidinones
|
Concept
|
Tumor Suppressor Proteins
|
Concept
|
Tubulin
|
Concept
|
Tumor Necrosis Factor-alpha
|
Concept
|
Poly(ADP-ribose) Polymerases
|
Concept
|
DNA Probes, HPV
|
Concept
|
Urokinase-Type Plasminogen Activator
|
Concept
|
Cysteine Proteinase Inhibitors
|
Concept
|
Tamoxifen
|
Concept
|
Receptors, Estrogen
|
Concept
|
Repetitive Sequences, Nucleic Acid
|
Concept
|
Tetracycline
|
Concept
|
DNA, Antisense
|
Concept
|
MAP Kinase Kinase Kinases
|
Concept
|
Serum Response Element
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
Concept
|
Epothilones
|
Concept
|
Retroviridae Proteins, Oncogenic
|
Concept
|
Single-Strand Specific DNA and RNA Endonucleases
|
Concept
|
Phosphoprotein Phosphatases
|
Concept
|
Sodium Salicylate
|
Concept
|
Anticarcinogenic Agents
|
Concept
|
Oncogene Proteins v-mos
|
Concept
|
Cell Cycle Proteins
|
Concept
|
Sulfonamides
|
Concept
|
Protein Tyrosine Phosphatases
|
Concept
|
Reactive Oxygen Species
|
Concept
|
Intercellular Signaling Peptides and Proteins
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
Megestrol Acetate
|
Concept
|
Apoptosis
|
Concept
|
Platinum Compounds
|
Concept
|
DNA, Complementary
|
Concept
|
Tretinoin
|
Concept
|
Chloramphenicol O-Acetyltransferase
|
Concept
|
Cyclin D1
|
Concept
|
Triazines
|
Concept
|
Vasoactive Intestinal Peptide
|
Concept
|
Proto-Oncogene Proteins c-kit
|
Concept
|
Proteome
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Retinal Dehydrogenase
|
Concept
|
STAT3 Transcription Factor
|
Concept
|
CCAAT-Enhancer-Binding Proteins
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
Stathmin
|
Concept
|
Cyclins
|
Concept
|
Receptors, CXCR4
|
Concept
|
Long Interspersed Nucleotide Elements
|
Concept
|
Anti-Mullerian Hormone
|
Concept
|
Transforming Growth Factor beta1
|
Concept
|
Papillomavirus E7 Proteins
|
Concept
|
Polycomb Repressive Complex 2
|
Concept
|
Cyclin-Dependent Kinase 4
|
Concept
|
Aquaporin 2
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 2
|
Concept
|
Retinoblastoma Protein
|
Concept
|
Free Radical Scavengers
|
Concept
|
GABA Plasma Membrane Transport Proteins
|
Concept
|
Erythroid-Specific DNA-Binding Factors
|
Concept
|
Drug Administration Schedule
|
Concept
|
Drug Screening Assays, Antitumor
|
Concept
|
Receptor, erbB-2
|
Concept
|
Proto-Oncogene Proteins c-met
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
Concept
|
Osteonectin
|
Concept
|
Folate Receptor 1
|
Concept
|
Calcium-Calmodulin-Dependent Protein Kinases
|
Concept
|
Mucin-1
|
Concept
|
Mitogen-Activated Protein Kinases
|
Concept
|
Topotecan
|
Concept
|
Matrix Metalloproteinases
|
Concept
|
GATA1 Transcription Factor
|
Concept
|
Ribonuclease III
|
Concept
|
Basic-Leucine Zipper Transcription Factors
|
Concept
|
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
|
Concept
|
Caspase 3
|
Concept
|
Elafin
|
Concept
|
Neoplasm Proteins
|
Concept
|
Caspase Inhibitors
|
Concept
|
Nanotubes, Carbon
|
Concept
|
Vascular Endothelial Growth Factor A
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
Concept
|
Tissue Inhibitor of Metalloproteinase-1
|
Concept
|
Cyclin A2
|
Concept
|
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p27
|
Concept
|
Proteasome Endopeptidase Complex
|
Concept
|
Tocopherols
|
Concept
|
Focal Adhesion Protein-Tyrosine Kinases
|
Concept
|
Forkhead Transcription Factors
|
Concept
|
LIM Domain Proteins
|
Concept
|
Hedgehog Proteins
|
Concept
|
Basic Helix-Loop-Helix Transcription Factors
|
Concept
|
Retinoid X Receptors
|
Concept
|
Transcription Factor RelA
|
Concept
|
TOR Serine-Threonine Kinases
|
Concept
|
CTLA-4 Antigen
|
Concept
|
Chemokine CXCL1
|
Concept
|
Peptides
|
Concept
|
Pyridones
|
Concept
|
Oligonucleotides, Antisense
|
Concept
|
Protein Isoforms
|
Concept
|
MicroRNAs
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Concept
|
G-Box Binding Factors
|
Concept
|
GPI-Linked Proteins
|
Concept
|
Niacinamide
|
Concept
|
Nuclear Proteins
|
Concept
|
Recombinant Fusion Proteins
|
Concept
|
Sphingosine
|
Concept
|
Integrins
|
Concept
|
Cytokines
|
Concept
|
Fenretinide
|
Concept
|
Receptors, Aryl Hydrocarbon
|
Concept
|
Receptor, Platelet-Derived Growth Factor beta
|
Concept
|
Oncogene Proteins v-raf
|
Concept
|
Symporters
|
Concept
|
Telomere-Binding Proteins
|
Concept
|
p38 Mitogen-Activated Protein Kinases
|
Concept
|
Transcription Factor CHOP
|
Concept
|
NF-kappa B p50 Subunit
|
Concept
|
p21-Activated Kinases
|
Academic Article
|
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
|
Academic Article
|
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
|
Academic Article
|
Targeting the Nuclear Import Receptor Kpn?1 as an Anticancer Therapeutic.
|
Academic Article
|
Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine.
|
Academic Article
|
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
|
Academic Article
|
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
|
Academic Article
|
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
|
Academic Article
|
Better therapeutic trials in ovarian cancer.
|
Academic Article
|
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
|
Academic Article
|
Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer.
|
Academic Article
|
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
|
Academic Article
|
Novel therapeutic targets.
|
Academic Article
|
An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.
|
Academic Article
|
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
|
Academic Article
|
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.
|
Academic Article
|
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
|
Academic Article
|
Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents.
|
Academic Article
|
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
|
Academic Article
|
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
|
Academic Article
|
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
|
Academic Article
|
Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
|
Academic Article
|
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
|
Academic Article
|
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
|
Academic Article
|
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
|
Academic Article
|
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
|
Academic Article
|
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.
|
Academic Article
|
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.
|
Academic Article
|
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
|
Academic Article
|
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
|
Academic Article
|
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
|
Academic Article
|
Ovarian cancer: targeting the untargetable.
|
Academic Article
|
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
|
Academic Article
|
Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.
|
Academic Article
|
Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes.
|
Academic Article
|
Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
|
Academic Article
|
NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
|
Academic Article
|
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
|
Academic Article
|
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
|
Academic Article
|
Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
|
Academic Article
|
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
|
Academic Article
|
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors.
|
Academic Article
|
Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
|
Academic Article
|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
|
Academic Article
|
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
|
Academic Article
|
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
|
Grant
|
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit
|
Academic Article
|
Growth factors and other targets for rational application as intervention agents.
|
Academic Article
|
PACAP stimulates c-fos mRNAs in small cell lung cancer cells.
|
Academic Article
|
Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation.
|
Academic Article
|
Use of transcription factors as agents and targets for drug development.
|
Academic Article
|
The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
|
Academic Article
|
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
|
Academic Article
|
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
|
Academic Article
|
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
|
Academic Article
|
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
|
Academic Article
|
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of M?llerian origin.
|
Academic Article
|
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
|
Academic Article
|
Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.
|
Academic Article
|
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary?analysis of FORWARD I.
|
Academic Article
|
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
|
Academic Article
|
A highly annotated database of genes associated with platinum resistance in cancer.
|
Academic Article
|
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
|